Antimicrobial resistance in ocular infection: A review

Clin Exp Ophthalmol. 2024 Apr;52(3):258-275. doi: 10.1111/ceo.14377. Epub 2024 Mar 17.

Abstract

Antimicrobial resistance (AMR) is a global public health threat with significant impact on treatment outcomes. The World Health Organization's Global Action Plan on AMR recommended strengthening the evidence base through surveillance programs and research. Comprehensive, timely data on AMR for organisms isolated from ocular infections are needed to guide treatment decisions and inform researchers and microbiologists of emerging trends. This article aims to provide an update on the development of AMR in ocular organisms, AMR in bacterial ocular infections and on AMR stewardship programs globally. The most common ocular pathogens are Pseudomonas aeruginosa, Staphylococcus spp., Streptococcus pneumoniae, and Haemophilus influenzae in ocular infections. A variety of studies and a few surveillance programs worldwide have reported on AMR in these infections over time. Fluoroquinolone resistance has increased particularly in Asia and North America. For conjunctivitis, the ARMOR cumulative study in the USA reported a slight decrease in resistance to ciprofloxacin. For keratitis, resistance to methicillin has remained stable for S. aureus and CoNS, while resistance to ciprofloxacin has decreased for MRSA globally. Methicillin-resistance and multidrug resistance are also emerging, requiring ongoing monitoring. Antimicrobial stewardship (AMS) programmes have a critical role in reducing the threat of AMR and improving treatment outcomes. To be successful AMS must be informed by up-to-date AMR surveillance data. As a profession it is timely for ophthalmology to act to prevent AMR leading to greater visual loss through supporting surveillance programmes and establishing AMS.

Keywords: antibiotics; antimicrobial resistance; corneal ulcer; endophthalmitis; keratitis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Ciprofloxacin / therapeutic use
  • Drug Resistance, Bacterial
  • Eye Infections, Bacterial* / microbiology
  • Humans
  • Methicillin / therapeutic use
  • Microbial Sensitivity Tests
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents
  • Methicillin
  • Ciprofloxacin

Grants and funding